Advertisement

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Advertisement

Advertisement




May
08
Today In Oncology
Curing Most Leukemias on the Horizon: A 5-Decade MD Anderson Perspective on Leukemia Research
Long-Term Outcomes With Maintenance Rucaparib in Advanced Pancreatic Cancer With BRCA or PALB2 Pathogenic Variants
Tiragolumab Plus Atezolizumab and Chemotherapy in Advanced Nonsquamous NSCLC
Appendiceal Cancer: Serum Tumor Marker Levels May Guide Treatment in Patients Undergoing CRS
High YAP1 Expression Leads to Chemotherapy Resistance Relapse in Treated SCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo